Botanix Pharmaceuticals (BOT) investor relations material

Executive summary

• Sofdra prescriptions reached 62,500 in the first 11 months, generating nearly $100 million in gross revenue and $21.2 million in net revenue since its February 2025 launch.

• The fulfillment platform exceeded expectations, enabling high fill rates, streamlined access, and high reimbursement rates for patients and physicians.

• Sales force expanded to 50 specialists, completed in Q2 FY26, driving prescription growth, demand, and compliance.

• Firm commitments secured for a AUD 45 million capital raise to support API purchases, marketing, and working capital.

• The company is focused on maximizing platform scalability and adding new assets to leverage operational efficiencies.

Financial highlights

• Net revenue for the half-year ending December 31, 2025, rose to AUD 16.2 million, a 219% increase from AUD 5.1 million in the prior half; total revenue, including royalties, reached AUD 16.5 million, up from AUD 346,000 year-over-year.

• Adjusted EBITDA loss for the half was AUD 26.1 million; loss before tax was AUD 33.2 million.

• Operating expenses totaled AUD 36.6 million, reflecting investments in sales, marketing, and headcount; total expenses increased 55% year-over-year to $50.4 million.

• Cash and equivalents at period end were AUD 31.6 million, down from $65.0 million at 30 June 2025.

• Net cash outflow from operating activities was $30.3 million, similar to the prior period.

Outlook and guidance

• Net revenue is expected to continue growing, supported by high physician intent to increase Sofdra prescribing and platform scalability.

• Gross-to-net yields are targeted to improve to 30%-40% as insurance clearance rates rise and platform efficiencies increase.

• Expansion into new regions and licensing opportunities are being pursued.

• Selection of an alternate API supplier is expected to reduce COGS by 25%-40% and smooth future cash outflows.

• The company aims to achieve profitability by leveraging platform efficiencies and adding new products.